Delighted to be reporting for @RheumNow LIVE from Milan 🇮🇹 #EULAR2023 alongside my esteemed colleagues @drdavidliew @Janetbirdope @jeffsparks @synovialjoints @AurelieRheumo @bella_mehta 🙌🏻 Do follow us for Congress coverage 😃 https://t.co/tmD4vVWnQk

#EULAR2023 Please find my first article on Congress Preview of Promising New Therapies in #lupus #SLE @RheumNow https://t.co/SFvhsP8QWO https://t.co/m5UwBGCXFB

A full house for the #EULAR2023 Opening session @eular_org setting the tone for an exciting few days to come! @RheumNow https://t.co/bZSIL78mU6

Watch: A Family History of Ankylosing Spondylitis https://t.co/3U7DG8P52c https://t.co/lxial62ujS

Watch: Evaluation of Sacroiliac Joint RheumNow Live: Prof. Denis Poddubnyy, Charité University Hospital, Berlin https://t.co/vH866d5sy6 https://t.co/zSMMBedyoG

Prevalence of PsA, Spondyloarthritis and Rheumatoid Arthritis in Norway Recent reports have suggested a rising and unrecognized number of patients with PsA and axSpA compared to RA. This has implications on diagnosis and population care. https://t.co/D0SvKP2MIa https://t.co/Gjh0oSZ5S2

Lupus Landmark Study to Accelerate Personalized Lupus Treatments The Lupus Landmark Study, the largest study of its kind in lupus, will prospectively recruit and longitudinally follow 3,500 adults diagnosed with SLE. https://t.co/nzCqk8AxK6 https://t.co/IS9OS08CmH

Tonight! The final Tuesday Night Rheumatology of May. This webinar will feature highlights from these lectures followed by live audience Q & A: Methotrexate Use: 50 Yr. Perspective Myths vs Reality in RA Biosimilars - Back on the Agenda https://t.co/NRAtlQ96e3 https://t.co/j6WVyFacUc

TAS5315, BTK inhibitor, studied in 91 MTX refractory RA pts. Wk 12 ACR20 resp was 79% on TAS5315 vs 60% PBO (p=0.053); ACR50 (33 vs 13%) not signif. Adverse event equal betw grps, but 9 pts had bleeding on TAS5315 https://t.co/XYS0XRMJar https://t.co/ntGtahFf4T

Vedolizumab (VED) doesnt help SpA. Study of 39 IBD, half on VED, 17 w/ SpA (7 axial). 14 w/ periph. arthritis before VED, only 3 improved w/ VED. 3 pts on VED developed new arthritis/aglas. 6 Pts stopped for SpA (2) or IBD (4) worsening. https://t.co/8BMTmJqhPq https://t.co/BOMsk38KB2

Systematic review proves Keystones 60%/40%/20% response rule in biologic-naive #RA. 21 RCTs 1999-2017; For bio-naïve pts the ACR20/50/70 was 61.4%/37.8%/ 18.8%. For Bio-IR it was 48.5%/27.3%/12.9%- roughly 10pts lower. https://t.co/Xr3QEw278J https://t.co/OAfNghXlvB